Eastspring Investments bought 6,26,000 shares of Biocon Limited for ₹25.04 crore at ₹400.00 apiece in a block deal.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
Asian asset management arm of Prudential plc, headquartered in Singapore. Runs multiple India strategies.